Metropolitan Life Insurance Co. NY cut its stake in shares of Masimo Co. (NASDAQ:MASI) by 40.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,009 shares of the medical equipment provider’s stock after selling 10,659 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Masimo were worth $1,563,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Masimo by 0.7% in the first quarter. BlackRock Inc. now owns 7,301,352 shares of the medical equipment provider’s stock valued at $642,154,000 after acquiring an additional 53,887 shares during the period. FMR LLC lifted its holdings in Masimo by 6,605.4% in the second quarter. FMR LLC now owns 1,821,994 shares of the medical equipment provider’s stock valued at $177,918,000 after acquiring an additional 1,794,822 shares during the period. Point72 Asset Management L.P. lifted its holdings in Masimo by 102.0% in the first quarter. Point72 Asset Management L.P. now owns 1,381,945 shares of the medical equipment provider’s stock valued at $121,542,000 after acquiring an additional 697,920 shares during the period. Old Mutual Global Investors UK Ltd. lifted its holdings in Masimo by 6.8% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 940,944 shares of the medical equipment provider’s stock valued at $82,756,000 after acquiring an additional 59,944 shares during the period. Finally, Champlain Investment Partners LLC lifted its holdings in Masimo by 248.8% in the first quarter. Champlain Investment Partners LLC now owns 692,780 shares of the medical equipment provider’s stock valued at $60,930,000 after acquiring an additional 494,180 shares during the period. 83.25% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently issued reports on MASI. Stifel Nicolaus lifted their price target on Masimo from $112.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. Needham & Company LLC began coverage on Masimo in a research note on Friday, September 14th. They set a “buy” rating for the company. BidaskClub raised Masimo from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 17th. Zacks Investment Research cut Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, August 1st. Finally, ValuEngine upgraded Masimo from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $109.20.

MASI traded up $2.51 during midday trading on Friday, hitting $117.13. The company’s stock had a trading volume of 379,288 shares, compared to its average volume of 524,720. The stock has a market capitalization of $6.45 billion, a price-to-earnings ratio of 47.81, a price-to-earnings-growth ratio of 2.91 and a beta of 1.00. Masimo Co. has a 52-week low of $80.69 and a 52-week high of $126.89.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, August 1st. The medical equipment provider reported $0.73 EPS for the quarter, beating the consensus estimate of $0.71 by $0.02. Masimo had a return on equity of 21.49% and a net margin of 15.30%. The company had revenue of $211.62 million during the quarter, compared to analysts’ expectations of $207.85 million. During the same quarter in the previous year, the business earned $0.83 EPS. The firm’s revenue was up 10.0% on a year-over-year basis. Equities research analysts predict that Masimo Co. will post 2.9 EPS for the current year.

In other news, Director Sanford Fitch sold 2,000 shares of the business’s stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $101.00, for a total transaction of $202,000.00. Following the completion of the sale, the director now owns 57,832 shares in the company, valued at approximately $5,841,032. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven Barker sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $110.00, for a total value of $1,100,000.00. Following the sale, the director now owns 74,832 shares of the company’s stock, valued at approximately $8,231,520. The disclosure for this sale can be found here. Insiders have sold a total of 765,380 shares of company stock valued at $90,720,456 in the last quarter. Company insiders own 12.60% of the company’s stock.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

See Also: Marijuana Stocks Future Looks Bright

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.